iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share

Earnings (Loss) Per Common Share

6 Months Ended

Dec. 31, 2013

Earnings (Loss) Per Common Share

Basic earnings per share (“EPS”) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted EPS, the denominator includes the weighted-average number of shares of common stock outstanding during the period, the weighted-average effect of the 1.2 million shares from the private placement offering, and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the EPS calculation (in thousands, except per share amounts):

	Three Months ended December 31,				Six Months ended December 31,
	2013		2012		2013		2012
Basic Numerator:

Loss available to common stockholders	$	(1,625)	$	(1,071)	$	(1,245)	$	(3,123)

Basic Denominator		63,984		47,767		60,338		47,767
Per Share Amount	$	(0.03)	$	(0.02)	$	(0.02)	$	(0.07)

For the three and six months ended December 31, 2013 and 2012, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share are the same. As of December 31, 2013, shares issuable which could potentially dilute future earnings included approximately 6.4 million stock options and 12.7 million warrants. As of December, 2012, shares issuable which could potentially dilute future earnings included approximately 6.7 million stock options and 21.0 million warrants.